Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1

Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects

Wright State University · NCT04520217

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–50 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
40
US sites recruiting
1
Study start
June 6, 2022
Record last updated
January 27, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is three-fold. First, researchers will assess whether subjects who have clinically abnormal reactions to sunlight (photosensitivity) have increased levels of microvesicle particles (MVP) following ultraviolet B (UVB) treatment to localized area of skin. Second, researchers will assess if topical application of the medicine imipramine will block UVB-induced MVP release. Third, researchers will assess if the topical cream will block UVB-induced increased erythema reactions (reddening of the skin).

Being studied: 4% Imipramine Cream; Base Cream

Conditions: Photosensitivity; Microvesicle Particle

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Female and Male adult subjects age 18 to 50
  • Must be able to give informed consent
  • Have access to stable transportation
  • All skin types on Fitzpatrick Scale (Type I-VI)
  • Self-Identified photosensitivity
  • Able to provide medical history and list of medications-control subjects will not be allowed to be taking a medication that is known to be photosensitizer.

Exclusion Criteria

  • Underlying diseases that could affect wound healing (e.g., uncontrolled diabetes mellitus)
  • Taking medications that are known photosensitizers (e.g., doxycycline) or anti-inflammatories (e.g., NSAIDS [except for low-dose aspirin] or steroids)
  • Utilizing imipramine or any other tricyclic antidepressant (oral or cream)
  • Utilizing topical anti-inflammatory or systemic agents (e.g., prednisone)
  • Large tattoos in the designated testing areas
  • Tanning bed use within last 3 months
  • Photodynamic Therapy or UVB treatments in past 3 months
  • Female Subjects: pregnant or nursing
  • History of abnormal scarring (i.e., keloids)

Recruiting US locations

Study contacts (from the official record)

  • Manager Clinical Research Operations · 937-245-7500 · pturesearch@wrightstatephysicians.org
  • Regulatory Specialist · 937-245-7500 · pturesearch@wrightstatephysicians.org
All healthy volunteers studies in Ohio →
Testing Use of Topical Imipramine in Reducing Ultraviolet B… (NCT04520217) | Bored Studies